However, the findings support that inhibition of PPARβ/δ-associated pathways may interfere with central leptin’s beneficial effects in the heart, which may be relevant in patients with conditions like generalized lipodystrophy where leptin therapy is used to mitigate cardiac hypertrophy [45]. This evidence concerns the gene LEP and generalized lipodystrophy.